当前位置: 首页 >> 检索结果
142. Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
作者: Chloe Orkin.;Peter J Ruane.;Malcolm Hedgcock.;Cyril Gaultier.;Marcelo H Losso.;Benoit Trottier.;Thomas Lutz.;Mark O'Reilly.;Mark Bloch.;Jihad Slim.;Moti Ramgopal.;Simiso Sokhela.;Karam Mounzer.;Hung-Chin Tsai.;Jorge Santana Bagur.;Xu Zhang.;Keith Aizen.;Kwanza Price.;Nicolas Margot.;Jairo M Montezuma-Rusca.;Peter Sklar.;Martin Rhee.;Pedro Cahn.; .
来源: Lancet. 2026年407卷10535期1249-1258页
Single-tablet regimens (STRs) revolutionised HIV-1 treatment, improving adherence and clinical outcomes; however, many people cannot take these due to resistance, contraindications, or drug-drug interactions, instead relying on complex multi-tablet regimens. Novel STRs are therefore needed. We aimed to evaluate the efficacy and safety of a novel STR, bictegravir-lenacapavir, in people with HIV-1.
151. Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
作者: Narumi Harada-Shoji.;Akihiko Suzuki.;Takanori Ishida.;Seiichiro Yamamoto.;Seiki Kanemura.;Takuhiro Yamaguchi.;Yoko Shiono-Narikawa.;Noriaki Ohuchi.; .
来源: Lancet. 2026年407卷10530期784-793页
The J-START randomised controlled trial found that adjunctive ultrasonography was associated with significantly higher rates of breast cancer detection than mammography alone. This report aims to evaluate the long-term effect of adjunctive ultrasonography screening on the cumulative incidence of advanced breast cancer as a prespecified secondary outcome of J-START.
157. The EAT-Lancet Commission: issues and responses.
作者: Robert Fungo.;Francis Zotor.;Andrew Prentice.;Habiba Hassan-Wassef.;Muhammad Ali Dhansay.;Hassan Aguenaou.;Aloysius Maduforo.;Kingsley K A Pereko.;Given Chipili.;Betrand Tambe.;Augustin Zeba.
来源: Lancet. 2026年407卷10530期758-759页 |